Clinical Trial

A Study of ZW251 in Participants With Advanced Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to find out if ZW251, an antibody-drug conjugate targeting glypican-3 (GPC3), is safe and can treat participants with advanced cancers, including hepatocellular carcinoma (HCC), squamous cell non-small cell lung cancer (NSCLC), or germ cell tumors (GCT).
Protocol Amendment History 2 changes
critical Primary endpoint(s) modified 2026-04-15
notable Trial sites expanded: 20 -> 23 locations 2026-04-15
Trial Details
NCT Number NCT07164313
Lead Sponsor Zymeworks BC Inc.
Conditions Hepatocellular Carcinoma, Squamous Cell Non-Small Cell Lung Cancer, Germ Cell Tumor
Enrollment 100 participants
Start Date 2025-10-21
Primary Completion 2027-09 (estimated)
Study Completion 2028-05 (estimated)
Updated on ClinicalTrials.gov 2026-05-07